Present and Future in Treatment of Hodgkin Lymphoma

1. DeVita VT - A selective history of the therapy of Hodgkin's disease, Br J Haematol. 2003; 122(5):718-27 (ISSN: 0007-1048)10.1046/j.1365-2141.2003.04541.xSearch in Google Scholar

2. Thomas RK, Re D, Wolf J, et al. - Part I: Hodgkin's lymphoma--molecular biology of Hodgkin and Reed- Sternberg cells, Lancet Oncol. 2004; 5(1):11-8 (ISSN: 1470-2045)10.1016/S1470-2045(03)01319-6Search in Google Scholar

3. Re D, Küppers R, Diehl V - Molecular pathogenesis of Hodgkin's lymphoma, J Clin Oncol. 2005; 23(26):6379-86 (ISSN: 0732-183X)10.1200/JCO.2005.55.013Search in Google Scholar

4. Connors JM - State-of-the-art therapeutics: Hodgkin's lymphoma, J Clin Oncol. 2005; 23(26):6400-8 (ISSN: 0732-183X)10.1200/JCO.2005.05.016Search in Google Scholar

5. Moskowitz CH, Nademanee A, Masszi T, et al. - Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebocontrolled, phase 3 trial; Lancet. 2015; 385(9980):1853-62 (ISSN: 1474-547X)10.1016/S0140-6736(15)60165-9Search in Google Scholar

6. Younes A, Bartlett NL, Leonard JP, et al. - Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas, N Engl JMed. 2010; 363(19):1812-21 (ISSN: 1533-4406)10.1056/NEJMoa100296521047225Search in Google Scholar

7. Ansell SM, Lesokhin AM, Borrello I, et al. - PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N Engl J Med. 2015; 372(4):311-9 (ISSN: 1533-4406)10.1056/NEJMoa1411087434800925482239Search in Google Scholar

8. Ansell S, Armand P, Timmerman JM, et al. - Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study (CA209-039), Blood 2015 126:58310.1182/blood.V126.23.583.583Search in Google Scholar

9. Chen R, Zinzani PL, Fanale MA, et al. - Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma, J Clin Oncol. 2017; 35(19):2125-2132 (ISSN: 1527-7755)10.1200/JCO.2016.72.1316579184328441111Search in Google Scholar

10. Moskowitz AJ, Schöder H, Yahalom J, et al. - PETadapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study; Lancet Oncol. 2015; 16(3):284-92 (ISSN: 1474-5488)Search in Google Scholar

11. Garcia-Sanz R, Sureda A, Alonso-Alvarez S, et al. - Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO), Blood 2015 126:58210.1182/blood.V126.23.582.582Search in Google Scholar

12. Cassaday RD, Fromm J, Cowan AJ, et al. - Safety and Activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/ Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Initial Results of a Phase I/II Trial, Blood 2016 128:183410.1182/blood.V128.22.1834.1834Search in Google Scholar

13. LaCasce AS, Bociek RG, Sawas A, et al. - Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma, Blood. 2018; 132(1):40-48 (ISSN: 1528-0020)10.1182/blood-2017-11-815183607358829703778Search in Google Scholar

14. Herrera AF, Moskowitz AJ, Bartlett NL, et al. - Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma, Blood. 2018; 131(11):1183-1194 (ISSN: 1528-0020)10.1182/blood-2017-10-811224585502129229594Search in Google Scholar

15. Ramchandren R, Fanale MA, Rueda A, t al. - Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study, Blood 2017 130:65110.1182/blood.V130.Suppl_1.651.651Search in Google Scholar

16. Wang CM, Wu ZQ, Wang Y, et al. - Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open- Label Phase I Trial, Clin Cancer Res. 2017; 23(5):1156-1166 (ISSN: 1078-0432).10.1158/1078-0432.CCR-16-136527582488Open DOISearch in Google Scholar